GeneMedicine Inc. announces appointment of Alain P. Rolland, Ph.D., as vice president, Gene Delivery Sciences to lead its expanded efforts in advanced gene delivery.THE WOODLANDS, Texas--(BUSINESS WIRE)--Nov. 20, 1996-- GeneMedicine Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :GMED) Wednesday announced that Alain P. Rolland, Ph.D., has been appointed as vice president, Gene Delivery Sciences, a new position at GeneMedicine. Rolland will be responsible for leading the company's expanded efforts in the development of pharmaceutically acceptable, non-viral gene delivery systems, according to according to prep. 1. As stated or indicated by; on the authority of: according to historians. 2. In keeping with: according to instructions. 3. GeneMedicine President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. Eric Tomlinson, D.Sc., Ph.D. "In recognition of our expanded efforts in gene delivery sciences and Dr. Rolland's proven leadership, I am very pleased to announce his appointment," Tomlinson said. "Alain has played a pivotal role in advancing the company's core delivery technologies including lipid-, peptide-, carbohydrate- and polymer-based gene delivery systems. "In developing a broad base of non-viral gene therapy technology, we aim to position GeneMedicine to be the gateway to non-viral gene therapy pharmaceuticals. As vice president, Gene Delivery Sciences, Alain will lead the company's development of synthetic gene delivery systems to help realize this aim." Rolland joined GeneMedicine as director, Gene Delivery in June 1993. Prior to joining GeneMedicine, he was head, Formulation Research at CIRD CIRD Circulo Islámico de la República Dominicana CIRD Chemical Information Resources Directory Galderma in France from 1989 to 1993. Prior to 1989, he was a visiting scientist at the Advanced Drug Delivery Research Center of Ciba-Geigy Pharmaceuticals, where he developed a number of technologies for the intracellular targeting of drugs. Rolland has published over 50 scientific articles and books in the fields of drug delivery and gene delivery, is the editor of Pharmaceutical Particulate Carriers: Therapeutic Applications, and holds several patents in the field of drug targeting and formulation. Rolland has received numerous international and national awards for scholarship. Rolland holds a Ph.D. degree in Pharmaceutical Sciences from Rennes University in France. GeneMedicine is engaged in the discovery and development of synthetic non-viral technology that enables genes to be used as therapeutics. The company's "gene medicines" are well-characterized pharmaceutical products designed for direct administration to patients to cause the production and distribution of therapeutic proteins within the body. Gene medicines are for acute or chronic use and may be administered through convenient and conventional routes, including intramuscular injection Noun 1. intramuscular injection - an injection into a muscle injection, shot - the act of putting a liquid into the body by means of a syringe; "the nurse gave him a flu shot" , inhalation or intravenous injection Noun 1. intravenous injection - an injection into a vein fix - something craved, especially an intravenous injection of a narcotic drug; "she needed a fix of chocolate" . The company's core delivery technology includes lipid-, peptide-, carbohydrate- and polymer-based gene delivery systems, each able to be applied to specific clinical targets. Gene medicines also incorporate novel DNA sequences that control the tissue-specificity, duration and level of functioning of administered genes. In addition, GeneMedicine has developed high-yield, low-cost and scalable integrated manufacturing processes for the production of its gene medicines for clinical use. The company's initial business focus is the development of gene medicines for treating certain cancers, pulmonary diseases, musculoskeletal disorders Musculoskeletal disorders (MSDs) can affect the body's muscles, joints, tendons, ligaments and nerves. Most-work related MSDs develop over time and are caused either by the work itself or by the employees' working environment. as well as nucleic acid nucleic acid, any of a group of organic substances found in the chromosomes of living cells and viruses that play a central role in the storage and replication of hereditary information and in the expression of this information through protein synthesis. vaccines for infectious disease Infectious disease A pathological condition spread among biological species. Infectious diseases, although varied in their effects, are always associated with viruses, bacteria, fungi, protozoa, multicellular parasites and aberrant proteins known as prions. . GeneMedicine is developing its products through corporate alliances with major biotechnology and pharmaceutical companies. The company has partnerships with Roche Bioscience in the areas of asthma, arthritis and transplant rejection transplant rejection Graft rejection, organ rejection, tissue rejection Immunology The constellation of host immune responses evoked when an allograft tissue is transplanted into a recipient; rejection phenomena may be minimized by optimal matching of MHC antigens and with Boehringer Mannheim for the development of gene medicines to treat head and neck cancers and melanoma. CONTACT: GeneMedicine Inc., The Woodlands Richard A. Waldron, 713/364-1150 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion